It is understood，As of August 21，94 pharmaceutical A -share companies realized net profit of 9.575 billion yuan，increased by 15.97%year -on -year。With the rapid development and competition of the pharmaceutical market，The research and development of domestic pharmaceutical companies is significantly increased。Statistics display，94 companies in the first half of the year's research and development expenses totaling 1.779 billion yuan，year -on -year increase is as high as 124.44%。

    From the perspective of the subdivision industry，The most powerful R & D power of chemical raw materials，R & D expenses in the first half of the year 301 million yuan，increased by 256.90%year -on -year; the traditional Chinese medicine industry also significantly increased My stake betting appinvestment stake sports betting appin product research and development，Total expenditure 598 million yuan，increased by 157.63%year -on -year。Compared with medicine，Insufficient research and development of medical devices and pharmaceutical business industries，The year -on -year increase was only 52.62%、20.66%。

    R & D ability is an important evaluation indicator to measure the future development of a pharmaceutical company，and the proportion of R & D expenditure in operating income is one of the common specific parameters。According to statistical data, it shows，R & D expenditure in the pharmaceutical industry accounts for 1.54%of revenue。Although this ratio is still lower，However, there are still obvious improvements from 0.80%in the same period last year。Current，​​Not stake sports betting apponly stake sports betting appthe new drugs are facing the challenges that can be successfully developed and entering the new market，Competition between mature products is becoming increasingly fierce，In this competitive environment，The research and development capabilities of domestic pharmaceutical companies will become the focus of its own development and establishing competitive advantages。